How does EZ1's PE Ratio compare to its peers?

EZ1 is expensive based on its Price-To-Earnings Ratio (54.1x) compared to the peer average (7.6x).

How does EZ1's PE Ratio compare vs other companies in the European Biotechs Industry?

EZ1 is expensive based on its Price-To-Earnings Ratio (54.1x) compared to the European Biotechs industry average (26.9x).

What is EZ1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate EZ1's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of EZ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

EZ1 (€0.13) is trading below our estimate of [[fair value]] (€0.65)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

EZ1 Stock Overview

Does not have significant operations. More details

EZ1 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 80.3% below our estimate of its fair value

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue ($26K)

Highly volatile share price over the past 3 months compared to the German market

Earnings have declined by 4.3% per year over past 5 years

Does not have a meaningful market cap (€12M)

My Notes

Capture your thoughts, links and company narrative

Enzon Pharmaceuticals, Inc. Competitors

Epigenomics

DB:ECX

€980.2k

2invest

XTRA:2INV

€67.3m

AEON Biopharma

NYSEAM:AEON

US$21.6m

Formycon

XTRA:FYB

€965.8m

Price History & Performance

Summary of share price highs, lows and changes for Enzon Pharmaceuticals
Historical stock prices
Current Share Price	US$0.13
52 Week High	US$0.18
52 Week Low	US$0.046
Beta	0.51
1 Month Change	86.76%
3 Month Change	44.32%
1 Year Change	58.75%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	39.56%

Recent updates

Shareholder Returns

	EZ1	DE Biotechs	DE Market
7D	5.0%	2.3%	0.3%
1Y	58.8%	-11.7%	8.4%

Return vs Industry: EZ1 exceeded the German Biotechs industry which returned -11.7% over the past year.

Return vs Market: EZ1 exceeded the German Market which returned 8.4% over the past year.

Price Volatility

Is EZ1's price volatile compared to industry and market?
EZ1 volatility
EZ1 Average Weekly Movement	28.2%
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: EZ1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: EZ1's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1981	n/a	Rick Feinstein	enzon.com

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.

Enzon Pharmaceuticals, Inc. Fundamentals Summary

How do Enzon Pharmaceuticals's earnings and revenue compare to its market cap?
EZ1 fundamental statistics
Market cap	€11.29m
Earnings (TTM)	€240.68k
Revenue (TTM)	€25.33k

54.1x

P/E Ratio

513.9x

P/S Ratio

Is EZ1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EZ1 income statement (TTM)
Revenue	US$26.00k
Cost of Revenue	US$0
Gross Profit	US$26.00k
Other Expenses	-US$221.00k
Earnings	US$247.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.0033
Gross Margin	100.00%
Net Profit Margin	950.00%
Debt/Equity Ratio	0%

How did EZ1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 03:13
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enzon Pharmaceuticals, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Hazlett	BMO Capital Markets U.S. (Historical)
Pamela Bassett	Cantor Fitzgerald & Co.
James Molloy	Caris & Company

Enzon Pharmaceuticals BST:EZ1 Stock Report